ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Spyre Therapeutics Inc

Spyre Therapeutics Inc (SYRE)

18.56
-0.09
(-0.48%)
At close: 12 March 7:00AM
18.56
-0.01
( -0.05% )
After Hours: 7:20AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
18.56
Bid
16.11
Offer
30.00
Volume
883,013
17.25 Day's Range 19.58
17.24 52 Week Range 47.97
Market Cap
Previous Close
18.65
Open
19.58
Last Trade
25
@
19.48
Last Trade Time
08:42:46
Financial Volume
US$ 16,184,499
VWAP
18.3287
Average Volume (3m)
604,843
Shares Outstanding
60,275,561
Dividend Yield
-
PE Ratio
-3.30
Earnings Per Share (EPS)
-5.62
Revenue
886k
Net Profit
-338.79M

About Spyre Therapeutics Inc

Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodie... Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and SPY230. It has nominated development candidates for SPY001 and SPY002. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4B7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a discovery-stage program focused on designing antibodies to bind to Interleukin 23 (IL-23). Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Spyre Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SYRE. The last closing price for Spyre Therapeutics was US$18.65. Over the last year, Spyre Therapeutics shares have traded in a share price range of US$ 17.24 to US$ 47.97.

Spyre Therapeutics currently has 60,275,561 shares in issue. The market capitalisation of Spyre Therapeutics is US$1.12 billion. Spyre Therapeutics has a price to earnings ratio (PE ratio) of -3.30.

SYRE Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.754.211117349817.8121.0317.2483505219.36630003CS
4-3.79-16.957494407222.3523.7517.2467352320.39856613CS
12-5.66-23.369116432724.2226.0117.2460484321.86664219CS
26-9.54-33.950177935928.140.2617.2458915126.21542921CS
52-18.5-49.919050188937.0647.9717.2453338828.4990441CS
1567.7571.692876965810.8147.9710.4249540928.13295329CS
2607.7571.692876965810.8147.9710.4249540928.13295329CS

SYRE - Frequently Asked Questions (FAQ)

What is the current Spyre Therapeutics share price?
The current share price of Spyre Therapeutics is US$ 18.56
How many Spyre Therapeutics shares are in issue?
Spyre Therapeutics has 60,275,561 shares in issue
What is the market cap of Spyre Therapeutics?
The market capitalisation of Spyre Therapeutics is USD 1.12B
What is the 1 year trading range for Spyre Therapeutics share price?
Spyre Therapeutics has traded in the range of US$ 17.24 to US$ 47.97 during the past year
What is the PE ratio of Spyre Therapeutics?
The price to earnings ratio of Spyre Therapeutics is -3.3
What is the cash to sales ratio of Spyre Therapeutics?
The cash to sales ratio of Spyre Therapeutics is 1.26k
What is the reporting currency for Spyre Therapeutics?
Spyre Therapeutics reports financial results in USD
What is the latest annual turnover for Spyre Therapeutics?
The latest annual turnover of Spyre Therapeutics is USD 886k
What is the latest annual profit for Spyre Therapeutics?
The latest annual profit of Spyre Therapeutics is USD -338.79M
What is the registered address of Spyre Therapeutics?
The registered address for Spyre Therapeutics is 1521 CONCORD PIKE, SUITE 201, NEW CASTLE, WILMINGTON, DELAWARE, 19803
What is the Spyre Therapeutics website address?
The website address for Spyre Therapeutics is www.spyre.com
Which industry sector does Spyre Therapeutics operate in?
Spyre Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
HCTIHealthcare Triangle Inc
US$ 0.5244
(61.35%)
12.69M
SSPEW Scripps Company
US$ 1.88
(31.47%)
738.95k
LGCLLucas GC Ltd
US$ 0.6957
(28.05%)
160.4k
RAYRaytech Holding Ltd
US$ 2.1001
(24.27%)
2.98M
ONEGOneConstruction Group Limited
US$ 2.71
(20.44%)
1.29k
HEPAHepion Pharmaceuticals Inc
US$ 0.0512
(-39.05%)
18.83M
SHLTSHL Telemedicine Ltd
US$ 1.65
(-36.54%)
6.15k
TNONTenon Medical Inc
US$ 1.24
(-17.88%)
1.05M
ZYXIZynex Inc
US$ 5.77
(-17.57%)
20.44k
WCTWellchange Holdings Company Limited
US$ 0.6286
(-12.06%)
794.02k
HEPAHepion Pharmaceuticals Inc
US$ 0.0512
(-39.05%)
18.83M
HCTIHealthcare Triangle Inc
US$ 0.5244
(61.35%)
12.69M
ICONIcon Energy Corporation
US$ 0.1069
(-7.04%)
4.75M
NVDANVIDIA Corporation
US$ 108.45
(-0.29%)
4.38M
SYRSSyros Pharmaceuticals Inc
US$ 0.12
(-11.76%)
3.87M

Your Recent History

Delayed Upgrade Clock